2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic …
L Mazzolai, G Teixido-Tura, S Lanzi, V Boc… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
[HTML][HTML] Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm–2023 update
SL Samson, P Vellanki, L Blonde, EA Christofides… - Endocrine Practice, 2023 - Elsevier
Objective This consensus statement provides (1) visual guidance in concise graphic
algorithms to assist with clinical decision-making of health care professionals in the …
algorithms to assist with clinical decision-making of health care professionals in the …
[HTML][HTML] Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6
Background: GLP-1 RA (glucagon-like peptide-1 receptor agonists), including semaglutide,
may reduce stroke risk in people with type 2 diabetes. This post hoc analysis examined the …
may reduce stroke risk in people with type 2 diabetes. This post hoc analysis examined the …
Benefits of GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists
RM Goldenberg, AYY Cheng, T Fitzpatrick, JD Gilbert… - Stroke, 2022 - Am Heart Assoc
People living with diabetes are at higher risk for stroke and have a poorer prognosis
following a stroke event than those without diabetes. Data from cardiovascular outcome …
following a stroke event than those without diabetes. Data from cardiovascular outcome …
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke? Discordance between randomised controlled trials and observational studies
AJ Scheen - Diabetes & Metabolism, 2023 - Elsevier
Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular
complication has been less carefully investigated than the risk of cardiovascular mortality …
complication has been less carefully investigated than the risk of cardiovascular mortality …
GLP-1 receptor agonists: a New Treatment in Parkinson's Disease
K Kalinderi, V Papaliagkas, L Fidani - International Journal of Molecular …, 2024 - mdpi.com
Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Recent
data highlight similarities between neurodegenerative diseases, including PD and type 2 …
data highlight similarities between neurodegenerative diseases, including PD and type 2 …
The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration
Y Li, EJ Glotfelty, T Karlsson, LV Fortuno… - Journal of …, 2021 - Wiley Online Library
Abstract Glucagon‐like peptide‐1 (GLP‐1) is best known for its insulinotropic action
following food intake. Its metabolite, GLP‐1 (9‐36), was assumed biologically inactive …
following food intake. Its metabolite, GLP‐1 (9‐36), was assumed biologically inactive …
The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression
Recently, there has been a great deal of excitement about new glucagon-like peptide 1
receptor (GLP-1R) agonists (eg, semaglutide and tirzepatide) that have received FDA …
receptor (GLP-1R) agonists (eg, semaglutide and tirzepatide) that have received FDA …